Acute Severe Colitis: Infliximab and/or Cyclosporine?

被引：6

作者：

Fabro, Mauro ^{[1
]}

Szabo, Hajnalka ^{[4
]}

Terrosu, Giovanni ^{[2
]}

Avellini, Claudio ^{[3
]}

Tabuso, Maria ^{[1
]}

Fiorino, Gionata ^{[4
]}

Sorrentino, Dario ^{[1
,5
]}

机构：

[1] Cattedra Gastroenterol, Dept Clin & Expt Pathol, I-33100 Udine, Italy

[2] Chairs Digest Surg, Udine, Italy

[3] Chairs Pathol, Udine, Italy

[4] Univ Udine, Sch Med, I-33100 Udine, Italy

[5] Univ Queensland Nambour, Nambour, Qld, Australia

来源：

CURRENT DRUG TARGETS | 2011年 / 12卷 / 10期

关键词：

Severe colitis; corticosteroids; cyclosporine; infliximab; colectomy; SEVERE ULCERATIVE-COLITIS; EVIDENCE-BASED CONSENSUS; INTRAVENOUS CYCLOSPORINE; RESCUE THERAPY; SEVERE ATTACKS; CORTICOSTEROIDS; MANAGEMENT; COLECTOMY; EFFICACY; DISEASE;

D O I：

10.2174/138945011796818234

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%. As of today, I.V. corticosteroids remain the 1(st)-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2(nd) - line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.

引用

页码：1448 / 1453

页数：6

共 32 条

[1]

Colectomy rate in acute severe ulcerative colitis in the infliximab era [J].

Aratari, A. ;

Papi, C. ;

Clemente, V. ;

Moretti, A. ;

Luchetti, R. ;

Koch, M. ;

Capurso, L. ;

Caprilli, R. .

DIGESTIVE AND LIVER DISEASE, 2008, 40 (10) :821-826

[2]

Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis [J].

Arts, J ;

D'Haens, G ;

Zeegers, M ;

Van Assche, G ;

Hiele, M ;

D'Hoore, A ;

Penninckx, F ;

Vermeire, S ;

Rutgeerts, P .

INFLAMMATORY BOWEL DISEASES, 2004, 10 (02) :73-78

[3]

Potential target of infliximab in autoimmune and inflammatory diseases [J].

Atzeni, Fabiola ;

Doria, Andrea ;

Carrabba, Mario ;

Turiel, Maurizio ;

Sarzi-Puttini, Piercarlo .

AUTOIMMUNITY REVIEWS, 2007, 6 (08) :529-536

[4]

Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis [J].

Bamba, Shigeki ;

Tsujikawa, Tomoyuki ;

Inatomi, Osamu ;

Nakahara, Tamio ;

Koizumi, Yusuke ;

Saitoh, Yasuharu ;

Sasaki, Masaya ;

Fujiyama, Yoshihide ;

Andoh, Akira .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (03) :494-498

[5]

Guidelines for the management of inflammatory bowel disease in adults [J].

Carter, MJ ;

Lobo, AJ ;

Travis, SPL .

GUT, 2004, 53 :v1-v16

[6]

Infliximab for patients with refractory ulcerative colitis [J].

Chey, WY .

INFLAMMATORY BOWEL DISEASES, 2001, 7 :S30-S33

[7]

Cohen RD, 1999, AM J GASTROENTEROL, V94, P1587

[8]

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis [J].

D'Haens, G ;

Lemmens, L ;

Geboes, K ;

Vandeputte, L ;

Van Acker, F ;

Mortelmans, L ;

Peeters, M ;

Vermeire, S ;

Penninckx, F ;

Nevens, F ;

Hiele, M ;

Rutgeerts, P .

GASTROENTEROLOGY, 2001, 120 (06) :1323-1329

[9]

The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients [J].

Feagan, Brian G. ;

Reinisch, Walter ;

Rutgeerts, Paul ;

Sandborn, William J. ;

Yan, Songkai ;

Eisenberg, Debra ;

Bala, Mohan ;

Johanns, Jewel ;

Olson, Allan ;

Hanauer, Stephen B. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (04) :794-802

[10]

Infliximab or cyclosporine for severe ulcerative colitis [J].

Hanauer, SB .

GASTROENTEROLOGY, 2005, 129 (04) :1358-1359

← 1 2 3 4 →